Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Hokkaido Quake Hits Wholesaler Price Negotiations as Sept. Deadline for Medical Fee Cuts Looms
September 10, 2018
- Sanofi to Focus on Increasing Prescriptions of Lantus XR Based on Results of Head-to-Head Comparison Study
September 10, 2018
- Xofluza Cuts Flu Symptoms, Vial Loads: Shionogi
September 7, 2018
- Ono to Divide Oncology Sales Force into Two Units as Opdivo Label Expands
September 7, 2018
- Giant Quake Disrupts Drug Production, Shipments in Hokkaido; Distributors Scramble to Ensure Supplies
September 7, 2018
- Huahai Already Developed New Manufacturing Process for Valsartan API, Says Japan Chief after JMA Criticism on Impurity Issue
September 6, 2018
- Sawai’s Abilify Generic Approved for Bipolar Disorder
September 6, 2018
- Lenvima Gets China OK for 1st Line HCC: Eisai/Merck
September 6, 2018
- I/O in Lung Cancer - 4: Bristol-Myers Looks to Regain Ground for Opdivo with Immunotherapy Combos
September 5, 2018
- FDA Snubs Sunovion’s ADHD Drug
September 4, 2018
- Life Science Institute to Initiate Exploratory Clinical Study of Muse Cell Product for Cerebral Infarction
September 4, 2018
- Thrombocytopenia Drug Mulpleta Now Available in US: Shionogi
September 3, 2018
- Yamaha Motor to Invest in Biotech Evec to Strengthen Presence in Biomedical Field
September 3, 2018
- Taisho’s Voluntary Early Retirement Program Attracts 948 Applicants
September 3, 2018
- Kowa’s Parmodia Most Heavily Pitched for GPs in June: Anterio
August 31, 2018
- Global Biologic Market Rises 13.9% to 18.6 Trillion Yen in FY2017 Driven by I/O Drugs
August 31, 2018
- With Bullish Maviret, AbbVie Aims for Double-Digit Growth to Join Top 20 in 2018
August 30, 2018
- South Korea OKs Lenvima for 1st Line HCC: Eisai
August 30, 2018
- Eisai/Biogen’s Alzheimer’s Drug Aducanumab Shows Continued Efficacy in Long-Term Extension PIb Study
August 30, 2018
- Imfinzi, Gazyva Now Available in Japan
August 30, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…